A University of Houston pharmacology researcher and expert in cardiac development has identified a new cause of - and repair ...

A University of Houston pharmacology researcher and expert in cardiac development has identified a new cause of—and repair for—left ventricular non-compaction, also known as spongy heart disease. The ...

Abbott received Europe’s CE mark for a dual-ablation catheter used to treat a common heart arrhythmia, the company said ...

Baptist Health has become the first health system in the state of Arkansas to participate in a clinical trial to evaluate a new treatment for advanced heart failure.

About LockeT Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and ...

Loss-of-function in epicardial proteins called Numb Family Proteins, leads to left ventricular noncompaction, or spongy heart, presenting ...

Preliminary results from the FULCRUM-VT trial point to a safer, more effective way to treat ventricular tachycardia—a dangerous heart rhythm disorder that can lead to sudden cardiac arrest.

BrainSpace, a medtech focused on neurological injuries and illnesses, received 501 (k) clearance from the FDA for its brain ...

Abbott's TactiFlex Duo Ablation Catheter, Sensor Enabled, is designed with dual-energy to treat atrial fibrillation patients with the most challenging cases It can ...

Supported by the Israel Innovation Authority, the study aims to speed right-ventricular assessment in suspected ...

City-based Kauvery Hospital launched advanced electroanatomical mapping technology on Thursday for the treatment of complex heart rhythm disorders, including atrial fibrillation and ventricular ...

AliveCor, the global leader in AI-powered cardiology, today announced it has received U.S. Food and Drug Administration (FDA) ...